From Yahoo Finance: 2025-04-29 16:05:00

Evercore ISI initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $5 price target. The company represents a true biotech investment with early-stage technology and a wide array of strategic options. Despite significant progress, the stock is trading at cash due to investor focus on derisked targets.

Source: TheFly

For more information on PRQR, visit TipRanks for Disclaimer & Disclosure and to Report an Issue.



Read more at Yahoo Finance: ProQR Therapeutics initiated with an Outperform at Evercore ISI